Document is current

Article History

Received: 29 September 2025

Revised: 5 February 2026

Accepted: 8 February 2026

First Online: 9 April 2026

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Boston Children’s Hospital Institutional Review Board (IRB-P00024211). Participants 18 years and older provided informed consent; participants younger than 18 years old provided assent in addition to parental/guardian consent. Participants were compensated with gift cards up to $250 based on completion of all study procedures.

: Not applicable, as this manuscript does not contain any individual person's data in any form (including individual details, images, or videos).

: Kiran Maski has been a consultant for Takeda Pharmaceuticals, Jazz Pharmaceuticals, Alkermes, Avadel, Eisai Pharmaceuticals, Zevra Therapeutics, Taysha Gene Therapies, Synchronicity Pharma, and Harmony Biosciences. She has received research funding from Jazz Pharmaceuticals and Harmony Biosciences. She receives NIH funding from NINDS 5R61NS130215-02.